Clinical Trial Update: A Study of CC312 for Relapsed/Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase 1 study evaluating CC312 for relapsed/refractory autoimmune diseases, including systemic lupus erythematosus, idiopathic inflammatory myo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CC312 (CC312)

Snippet

Sponsor: CytoCares Inc | Conditions: SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies | EARLY_Phase 1 | Status: RECRUITING